Compare KE & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KE | NMRA |
|---|---|---|
| Founded | 1961 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 617.2M | 554.0M |
| IPO Year | 2014 | 2023 |
| Metric | KE | NMRA |
|---|---|---|
| Price | $26.25 | $2.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $28.00 | $6.57 |
| AVG Volume (30 Days) | 108.9K | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.23 |
| EPS | ★ 0.55 | N/A |
| Revenue | ★ $1,486,727,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.57 | N/A |
| P/E Ratio | $47.78 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.85 | $0.63 |
| 52 Week High | $33.19 | $3.65 |
| Indicator | KE | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 61.88 | 33.77 |
| Support Level | $26.23 | $1.79 |
| Resistance Level | $27.02 | $2.20 |
| Average True Range (ATR) | 0.88 | 0.16 |
| MACD | 0.34 | -0.01 |
| Stochastic Oscillator | 87.74 | 22.64 |
Kimball Electronics Inc is a contract electronic manufacturing services company. The company is engaged in producing durable electronics for the automotive, medical, industrial, and public safety end markets. The company's engineering, manufacturing, and supply chain services utilize common production and support capabilities. It is also engaged in producing safety-critical electronic assemblies for its automotive customers. Geographically, it has business units located in the United States, China, Mexico, Poland, Romania, and Thailand. The company derives maximum revenue from Mexico.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.